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Abstract  
Hyaluronic acid (HA) is an attractive biomaterial for osteoarthritis (OA) treatment due to inherent 
functional and compatibility properties as an endogenous knee joint component. In this work, we describe a 
HA-based hydrogel with the dual functionality of increased CD44-dependent chondrocyte binding and 
controlled release of gapmer antisense oligonucleotides for unassisted cellular entry and subsequent gene 
silencing activity. A Schiff base-mediated gelation method was used to produce a panel of hydrogels varying 
in the aldehyde-modified HA (900 kDa) to chitosan ratios (3:7, 5:5 and 7:3) for identifying designs displaying 
optimal engagement of OA patient-derived CD44-expressing chondrocytes. Correlation was found between 
cell binding and CD44 expression, with maximal binding exhibited at a HA/chitosan ratio of 7:3, that was 
181 % higher than CD44-negative MCF-7 cell control cells. Transfection agent-free uptake into OA 
chondrocytes of fluorescent 13-mer DNA oligonucleotides with a ﬂanked locked nucleic acid (LNA) gapmer 
design, in contrast to naked siRNA, was demonstrated by confocal and flow cytometric analysis.  A sustained 
and complete release over 5 days was found with the 7:3 hydrogel, in contrast, the 5:5 and 3:7 hydrogel released 
60 % and 43 % of loaded gapmers, respectively over the same period. A COX-2-specific gapmer designed 
with maximal chondrocyte gene silencing (~ 70 % silencing efficiency at 500 nM compared with a mismatch 
gapmer sequence) resulted in effective COX-2 silencing over 14 days in hydrogels seeded with OA 
chondrocytes, with significant difference exhibited between day 3 and 10. This work introduces a novel HA-
based CD44-mediated cellular binding and gapmer controlled release platform to modulate cellular gene 
expression.     
 
 
 
1. Introduction 
Osteoarthritis (OA) is a degenerative joint disorder that affects up to 50 %  of the US population over 50 
years of age [1]. Currently no disease modifying treatments are available, and in end stage disease, arthroplasty 
is the only option. The synthetic activity of OA chondrocytes, which are the cellular components of the joint 
cartilage and considered to be terminally differentiated cells that maintain the extracellular matrix of the 
cartilage, is clearly increased but cannot counteract the ongoing catabolic processes [2]. 
Inflammation is thought to play a key role in the pain associated with OA and the induction of various 
extracellular matrix degrading enzymes that leads to the cartilage tissue degradation are linked with aberrant 
expression of inflammation-related target genes such as cyclooxygenase-2 (COX-2) [3, 4]. Maintaining the 
regenerative capacity of OA chondrocytes, whilst interrupting the production of inflammatory genes such as 
COX-2, is, therefore, an attractive therapeutic approach. Present anti-inflammatory treatments based on direct 
intra-articular injection of drugs such as corticosteroids only elicit short-term effects and non-specific in action 
[5, 6]. In this work we propose a strategy based on a drug releasing platform able to interact and increase 
therapeutic delivery into chondrocytes. 
RNA interference-based post-translational gene silencing with double stranded small interfering RNA 
(siRNA) offers the possibility of cytokine-specific reduction of activity, in contrast to global 
immunosuppression commonly associated with traditional anti-inflammatory drugs. The macromolecular size 
and polyanionic nature, however, requires delivery technologies such as cationic lipids or polymers to facilitate 
cellular entry, which necessitates careful design considerations to avoid toxicity [7]. Single stranded gapmer 
oligonucleotides are chimeric antisense oligonucleotides, containing a central block of deoxynucleotide 
monomers commonly flanked by a locked nucleic acid (LNA) sequence that interrupt mRNA expression by 
induction of RNase H activation [8, 9]. Significantly, the small size (11~ 13 nucleotides) allows unassisted 
cellular entry by gymnosis, without any requirement for a transfection agent. Moreover, fatty acid 
modifications of the gapmers have been shown to enhance the gene silencing efficiency, such as ω-6 
polyunsaturated fatty acids and oleic acids [10]. 
The use of hydrophilic polymeric hydrogel drug releasing platforms are an attractive approach in OA due 
to combined flexible mechanical properties that can serve as scaffold for tissue regeneration and partly mimic 
the cartilage. Hyaluronic acid (HA) is an endogenous synovial fluid component that lowers frictional forces in 
the knee joint that has recently been applied in OA research  [11-13]. An unexplored HA property in OA 
treatment, however, is the ability to utilize the specific binding properties of HA for the CD44 receptor [14, 
15] shown to be strongly expressed on bovine chondrocytes and normal human articular chondrocytes [16]. 
Previous work from our lab has demonstrated that the level of CD44 binding can be tuned by the HA molecular 
weight, with optimal engagement observed with high molecular weight HA [17] that offers a potential novel 
application using engineered HA hydrogel scaffolds for chondrocyte binding. This, combined with a capacity 
for sustained delivery of gapmers to inhibit COX-2 without the necessity of a transfection agent offers a novel 
dual functional platform for cartilage repair and interruption of damage progression. 
In this work oxidized high molecular weight HA (900 kDa) was cross-linked with chitosan to form an in 
situ hydrogel by a Schiff reaction for CD44-mediated chondrocytes binding studies using CD44-expressing 
human primary chondrocytes and isogenic MCF-7 CD44-expressing and CD44-negative cells. Optimal COX- 
designs identified in an in vitro screen were then loaded into the hydrogel to study the release profiles and 
subsequent anti-inflammation effects in IL-1β induced OA chondrocytes over a 2-week period.  
 
  
2. Materials and Methods 
2.1 Materials 
Chitosan (degree of deacetylation >90%, Mw 200-600 kDa) was purchased from Novamatrix, Sandvika, 
Norway. Hyaluronic acid (HA) (Mw 900 kDa) was purchased from Lifecore biomedical, Chaska, USA, 
CyQuant cell proliferation kit from ThermoFisher Scientific, Waltham, USA and sodium periodate, t-butyl 
carbazate, β-glycerol phosphate disodium salt, ethylene glycerol, hyaluronidase and anti-CD44 FITC antibody 
from Sigma-Aldrich. Ultrapure water (Siemens Ultra Clear Basic plus) was used in all experiments. 
COX-2 antisense oligonucleotides (ASOs) gapmer sequences used: Gapmer design 1: 5’-lGlGlAlT 
dGdCdCdAdGdTdGdAdTdA lGlAlGlG-3’, Gapmer design 2: 5’-lGlGlAlT dGdCdCdAdGdTdGdA 
lTlAlGlA-3’, palmitoylated gapmer design 3: 5’-lGlGlAaT dGdCdCdAdGdTdGdA aTlAlGlA-3’, Gapmer 
design 4: 5’-lGlGlA dAdAdCdAdTdCdGdAdC lAlGlT-3’.  Cy5 labelled gapmer: 5’-lGlGlAlT 
dGdCdCdAdGdTdTdA lGlAlGlG-3’, Cy5 labelled palmitoylated gapmer: 5’-lGlGlA 
aTdGdCdCdAdGdTdGdAaT lAlGlA, FAM labelled gapmer: 5’-lGlGlA dAdAdCdAdTdCdGdAdC lAlGlT-
3’ (l – locked nucleic acid, d – deoxyribonucleotide, a – palmitoylated amino locked nucleic acid). All ASO 
were synthesized as all-phosphorothioate linked sequences except for the Cy5 labelled palmitoylated gapmer 
which was synthesized as all-phosphordiester linked sequence. ASOs were dissolved in nuclease-free water 
(Ambion, Austin, TX) to 200 µM concentrations measured by an Implen NanoDrop (Thermo Scientific, and 
stored at -20°C. siRNA was purchased from Genepharma (Shanghai, China) with the following sequences for 
the COX-2 siRNA-sense strand: 5’-CAUUCCCUUCCUUCGAAAUdTdT-3’ and antisense strand: 5’-
AUUUCGAAGGAAGGGAAUGdTdT-3’. siRNA was diluted using nuclease-free water. The 
phosphoramidite building block used to incorporate the palmitoylated amino locked nucleic acid thymine 
monomer is commercially available from RiboTask ApS (www.ribotask.com).  
Primary chondrocytes were isolated from articular cartilage of OA patients undergoing total knee 
arthroplasty. A CD44-negative MCF-7 cell line was derived from the original MCF-7 cell line (obtained from 
ATCC) via subcloning after stable insertion of a sequence suitable for subsequent Flp-recombinase-mediated 
insertion of expression plasmids. The cell line was used to insert the coding sequence (CDS) of the standard 
variant of CD44, known as CD44S or CD44 isoform 4 (NM_001001391.1; Consensus CDS CCDS31457.1) 
under the control of a constitutive cytomegalovirus promoter, which yielded the CD44-expressing cells [17].  
 
2.2 Synthesis of aldehyde modified hyaluronic acid 
Aldehyde-HA was synthesized by an oxidization method described previously [13]. Briefly, 1.0 g HA 
(2.5 mmol) was dissolved in 100 mL deionized water at a concentration of 10 mg/ml. 0.54 g sodium periodate 
(2.5 mmol) was dissolved in 5 ml deionized water and added dropwise into the HA solution under stirring in 
the dark. After 2 h, 1 ml of ethylene glycol was added into the reaction system to neutralize the excess amount 
of sodium periodate, and stirred for a further 1 h. The aldehyde-HA product was then dialyzed for 3 days 
against deionized water (changed daily) and then freeze-dried. The oxidation degree of HA was determined 
by a t-butyl carbazate method described previously [18]. 
 
2.3 Preparation of hyaluronic acid/chitosan hydrogels 
200 mg chitosan was dissolved in 9ml 0.1 M HCl solution, and then 1 ml of 560 mg β-glycerol phosphate 
solution added dropwise on ice, resulting in a chitosan solution at neutral pH  [19]. Aldehyde-HA (HA) was 
dissolved in deionized water at a concentration of 20 mg/ml. Both the HA solution and chitosan solution were 
sterilized by UV irradiation before mixing. The hydrogel was prepared by mixing HA and chitosan solutions 
at different volume ratios (3:7, 5:5 and 7:3) and gelation initiated spontaneously upon mixing. HA solution 
and chitosan solution were mixed in 24-well plate wells in a total volume of 500 μl and incubated for 10 
minutes to enable complete gelation. For gapmer incorporation, 4 nmol gapmers were first mixed with the HA 
solution, after which the HA/gapmer solution was mixed with the chitosan solution on ice. 
 
2.4 Determination of CD44 expression in primary chondrocytes and isogenic MCF-7 cells 
All cells were cultured at 37 °C under 5 % CO2 in a water saturated atmosphere. For chondrocyte culture, 
Dulbecco’s Modified Eagle’s Medium (DMEM D6429) with 1 % Penicillin-Streptomycin and 10 % heat-
inactivate fetal bovine serum was used. MCF-7 (passage 2-8) media was composed of DMEM Glutamax 
medium supplemented with fetal bovine serum (10%), Streptomycin/Penicillin (1 %), insulin (10 μg ml−1), and 
from the fourth day post plating the MCF-7, media was supplemented with hygromycin (120 μg ml−1). 
OA Chondrocytes and isogenic MCF-7 cells (CD44-expressing and CD44-negative) were seeded at 1 x 
105 cells/well in a 12-well plate. The following day, cells were trypsinized and incubated with 5 ul Anti-CD44 
FITC antibody in 100 μl blocking buffer ((3 % BSA in phosphate buffered saline (PBS) solution)) for 30 mins. 
After 3 times wash with blocking buffer, the cells were resuspended in PBS and the fluorescence intensity 
determined by flow cytometry using a Gallios (Beckman Coulter) flow cytometer with a 488 nm laser. The 
cell population gate was based on forward and side scattering, and was gated to distinguish dead cells and cell 
doublets. Events was set to 10000 for each measurement and samples were in triplicate. 
 
2.5 Cellular binding to the hyaluronic acid-based hydrogel  
OA chondrocytes, CD44-expressing and negative MCF-7 cells were selected to compare the CD44-
dependent binding of the HA-based hydrogel. HA and chitosan solutions of different ratios (3:7, 5:5 and 7:3) 
were pipetted into a 12-well plate to form hydrogels and 5 x 104 cells were then seeded on top in 0.5 ml media. 
After 36 h incubation, the media was changed to remove unattached cells, and fresh medium containing 100 
U/ml hyaluronidase was then added and incubated for 5 h for hydrogel digestion. The supernatants containing 
cells attached to the hydrogel were collected and the wells (with remaining attached cells) were treated with 
200 ul trypsin for 5 min. The mixtures of supernatant and trypsin were then centrifuged and lysed for CyQuant 
cell proliferation assay. All the cell numbers of different cell types were normalized to the numbers of 
corresponding cells plated in wells to eliminate the difference in proliferation rates.  
A 3-(4, 5-dimethylthiazol-2-y1)-2, 5-diphenyltetrazolium bromide (MTT) assay was used to determine 
cell viability of chondrocytes attached to the hydrogels. Collected chondrocytes pellets from the hydrogels 
were treated with 200 μl MTT (5 mg/ml), and incubated for 3 h at 37 °C. Formazan crystals were then dissolved 
in 150 μl of dimethyl sulfoxide (DMSO). The absorbance at 570 nm was measured with a Victor X5Multilabel 
plate reader (PerkinElmer) and live cell numbers were calculated by a calibration curve from a non-treated 
group. Total cell numbers were determined using a NucleoCounter® NC-200 (ChemoMetec) and viabilities 
were calculated as percentage of live cells/total cells. 
 2.6 Cellular uptake of gapmer oligonucleotides determined by flow cytometric and confocal microscopic 
analysis  
1 x 105 OA chondrocytes were seeded in a 24-well plate. After 24 h, 50 nM or 100 nM Cy5 labelled 
gapmers (non-modified gapmer: 5’-lGlGlAlT dGdCdCdAdGdTdTdA lGlAlGlG-3’, palmitoylated gapmer: 5’-
lGlGlA aTdGdCdCdAdGdTdGdAaT lAlGlA) and 50 nM naked siRNA were added to the media. The media 
was removed after 24 h and chondrocytes were washed 3 times with PBS. The chondrocytes were then 
trypsinized, and the fluorescence intensity determined by flow cytometry using a 633 nm laser.   
For confocal microscopic studies, 1 x 105 OA chondrocytes were seeded in a 24-well plate. After 24 h, 
50 nM or 100 nM FAM labelled non-modified gapmer (5’-lGlGlA dAdAdCdAdTdCdGdAdC lAlGlT-3’) were 
added to the media. The media was removed after 24 h and the cells were washed twice with PBS, harvested 
by tripsinization and fixed with 4% paraformaldehyde for 15 min, permeabilized and stained with Hoechst 
33342 and phalloidin (Life technologies) before confocal microscopic analysis using a LSM700 (Zeiss). 
 
2.7 COX-2 cellular gene silencing in vitro 
OA chondrocytes were seeded at 1 x 105 in a 6-well plate and 10 ng/ml IL-1β added for induction of 
inflammation at day 0 and day 7. After 24 h, 500 nM naked COX-2 gapmer (4 designs) or 50 nM COX-2 
siRNA (antisense strand: 5’-AUUUCGAAGGAAGGGAAUGdTdT-3’) with 4 μl lipofectamine were added 
into the media and incubated for another two days before RNA extraction. The COX-2 mRNA expression level 
was quantified by real time polymerase chain reaction (PCR), normalized to Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). Thermal cycling conditions were 48 °C for 15 min of activation, 95 °C for 10 min 
of amplification and 40 cycles of 95 °C at 15 s denaturing and 60 °C at 60 s annealing/extending. COX-2 
forward primer: 5’-TGGCTACAAAAGCTGGGGAAG-3’, reverse primer: 5’-
AACTGATGCGTGAAGTGCTG-3’. GAPDH forward primer: 5’-GTCAGCCGCATCTTCTTTTG-3’, 
reverse primer: 5’-GCGCCCAATACGACCAAATC-3’.  
For cell viability evaluation, chondrocytes were seeded in a 48-well plate at a density of 1×104/well. The 
cells were treated with 500 nM gapmers or 50 nM siRNA with 4 μl lipofectamine for 24 h. Subsequently, MTT 
assay was performed as described in section 2.5 and viabilities were normalized to a non-treated group. 
 
2.8 Gapmer oligonucleotide release profiles and in vitro COX-2 inhibition after inclusion within a hyaluronic 
acid-based hydrogel  
Hydrogels of different HA: chitosan ratios (3:7, 5:5 and 7:3) were prepared to modulate the gapmer 
release profiles. 50 μg Cy5 labelled gapmer (7.5 nmol, 5’-lGlGlAlT dGdCdCdAdGdTdTdA lGlAlGlG-3’) was 
added into the HA solution and mixed with chitosan solution in a 12-well plate to form hydrogel at a total 
volume of 2 ml, and the hydrogels were then incubated in 1 ml PBS.  At different time points over a 5 day 
period, 1 ml of PBS was removed and the fluorescence intensity determined by a Victor X5Multilabel plate 
reader (PerkinElmer). The hydrogel incubation buffer was replenished with 1 ml fresh PBS after each reading. 
At day 6, 100 U/ml hyaluronidase was added to 1 ml PBS in order to digest the hydrogel and the supernatants 
collected for fluorescence analysis. A calibration curve of the same Cy5 gapmers was made to quantify the 
amount of released gapmer. Loading efficiency of gapmers in hydrogels were determined by a depletion 
method, as total released gapmers and gapmers in digested solutions were summed up to be total encapsulation 
amount.  
The capability for hydrogel released gapmers to reduce COX-2 expression in                                                                 
OA chondrocytes was investigated 1 x 105 OA chondrocytes were seeded in 6-well plates, and 10 ng/ml IL-
1β was added into the medium to induce inflammation at day 0 and day 7. Two mls of the hydrogel (HA: 
chitosan 7:3) containing 4 nmol anti-COX-2 gapmer design 1 (5’-lGlGlAlT dGdCdCdAdGdTdGdAdTdA 
lGlAlGlG-3’) was pipetted into the wells to overlay the seeded cells, and the media changed every 3 days. A 
mismatch gapmer group and IL-1β free group were used as controls. At different time points, total RNA was 
extracted and COX-2 mRNA expression levels were determined by PCR as in the above section 2.7.  
 
 
 
2.9 Statistical analysis  
A one-way ANOVA was used for cellular binding and COX-2 inhibition experiments with each 
experiment performed twice. The data is presented as means ± standard error of the mean. Differences were 
considered to be significant at a p value of 0.05. 
3. Results 
A panel of hydrogels was constructed from different ratios of chitosan and aldehyde modified HA 
introduced to HA by oxidation of sodium periodate. The vicinal hydroxyl groups were oxidized to dialdehydes 
by opening the sugar ring. The mole ratio between HA monomer and oxidant was 1:1, with ~ 38.6% of the 
hydroxyl groups oxidized determined by a t-butyl carbazate method.  
β-glycerol phosphate was added to the chitosan in 0.1 M HCl to neutralize the acidic solution and maintain 
the chitosan in soluble form as a result of glycerol moiety separating the chitosan chains to maintain solubility 
[20]. After the addition of 560 mg β-glycerol phosphate solution, the pH increased from 3.9 to 7.0, which was 
close to physiological pH value. The hydrogel gelated on mixing the chitosan with the HA solution due to a 
Schiff base reaction, with the HA aldehyde groups cross-linking with carboxyl groups on chitosan.  
The fluorescent intensity of an anti-human CD44 fluorescent antibody using flow cytometry was used to 
determine the CD44 expression level on the different cell types. CD44-negative MCF-7 cells did not show any 
antibody binding but the CD44-expressing MCF-7 showed CD44 expression (Supplementary Figure 1). A 5.6-
fold higher expression of CD44 was found in primary chondrocytes compared to the CD44-expressing MCF-
7 cell line that supports the approach for CD44-dependent chondrocyte binding into an HA hydrogel matrix. 
This was investigated with the panel of cells seeded onto hydrogels ranging in HA content. Overall 
chondrocyte viability was around 75-80 % after 36 h incubation on the hydrogels (Supplementary Figure 2). 
All the cell numbers of different cell types were normalized to the numbers of corresponding cells plated in 
wells to eliminate difference of cell proliferation rates. Significant differences in binding was found for OA 
chondrocytes than the CD44-expressing and CD44-negative MCF-7 cells (Figure 1), with higher binding found 
with the higher CD44 expression. In the HA/chitosan 7:3 hydrogel, the chondrocyte normalized number was 
181 % higher than CD44-negative MCF-7 cells and 100 % higher than low CD44-expressing MCF-7 cells, 
respectively. In the HA/chitosan 5:5 hydrogel, normalized chondrocytes number was 200 % higher than CD44-
negative MCF-7 cell, but normalized total chondrocyte number decreased from 1.19 to 0.79 by 34 % compared 
with 7:3 group. In the HA/chitosan 3:7 hydrogel, no significant difference of cell numbers was found between 
the cells differing in CD44 expression, which supports the cell number differences were attributed to the 
dependency on the CD44-HA interaction.  
 Fig. 1. Cellular binding to hydrogels composed of different HA: chitosan ratios (7:3, 5:5 and 3:7). 
Chondrocytes, CD44-expressing and CD44-negative MCF-7 cells were seeded on hydrogels and incubated 
for 36 h. After 3 x PBS wash, binding cell numbers were determined and normalized to attached cell numbers 
in plate wells (N=3). Asterisk denotes statistical significance. 
The ability of fluorescent labelled gapmer oligonucleotides to associate and enter OA chondrocytes 
without the requirement of a transfection agent was validated by flow cytometry and confocal microscopy 
(Figure 2). Non-modified gapmers showed a 5-fold higher association compared with palmitoylated modified, 
whilst naked siRNA and non-treated group showed no fluorescent signals (Figure 2). Treatment of 100 nM 
gapmers showed a higher cellular association with OA chondrocytes than 50 nM, 1.8-fold increase for non-
modified gapmer and 1.75-fold increase for palmitoylated gapmer respectively. OA chondrocytes incubated 
for 24 h with either 50 or 100 nM gapmer showed green fluorescence throughout the cytoplasm that was absent 
from the nucleus (Figure 2).  
 Fig. 2. Cellular uptake of fluorescence-labelled gapmer oligonucleotides in primary OA chondrocytes. 
Cy5 labelled gapmers (50 and 100 nM), with and without palmitoylation, were incubated with primary OA 
chondrocytes for 24 h, and fluorescence intensity determined using flow cytometry. Naked Cy5 labelled siRNA 
at a concentration of 50 nM was used as a negative control. Flow cytometer was determined with a laser 
wavelength of 633 nm and gate events of 10000 (N=3). Insert: Left panel shows primary OA chondrocytes 
with 50 nM gapmer without palmitoylation, and right panel shows primary OA chondrocytes with 100 nM 
gapmer without palmitoylation. Nuclei were stained with Hoechst (blue), actin filaments were stained with 
phalloidin (red) and gapmer were labelled with FAM (green). Original magnification 20x. 
A panel of COX-2 specific gapmer designs of different sequences, with or without palmitoylation, were 
screened in OA chondrocytes for unassisted (without transfection agent) gene silencing compared to a COX-
2 siRNA with lipofectamine transfection (Figure 3). Successful silencing of target gene COX-2 (~82 % 
silencing efficiency) was seen in vitro for the lipofectamine-mediated siRNA positive control. The silencing 
efficiency of different gapmer sequences were different dependent on design with gapmer design 1 (5’-
lGlGlAlT dGdCdCdAdGdTdGdAdTdA lGlAlGlG-3’) exhibited the highest silencing efficiency of 70 % and 
gapmer design 3 was 33 %. A 10-fold higher concentration was required for unassisted gapmer silencing 
compared with lipofectamine-mediated siRNA. Gapmer design 1 showed a better knockdown compared to 
palmitoylated gapmer design 3 mainly attributed to different nucleotides in sequences. It should be noted that 
exchange of two LNA nucleotides of gapmer design 2 with two palmitoylated amino-LNA nucleotides to give 
gapmer design 3, makesan inactive ASO into an active one (gapmer design 3). Moreover, the four gapmers 
displayed a higher chondrocyte viability of 85-95% (92.3 %, 94.2 %, 88.5 and 84.6 % respectively) compared 
with siRNA (73%) transfected with lipofectamine evaluated by an MTT assay (Supplementary Figure 3). 
Gapmer design 1 was used for subsequent experiments based on the in vitro cellular gene silencing screen. 
 
Fig. 3. COX-2 cellular gene in vitro using different gapmer oligonucleotide designs in primary OA 
chondrocytes. Primary OA chondrocytes were treated with 500 nM gapmers of different designs. After 24 h 
incubation, 10 ng/ml IL-1β was added to induce inflammation. After 4 days incubation, the RNA was extracted 
for real time PCR analysis to determine COX-2 gene expression levels. COX-2 siRNA with lipofectamine 2000 
was used as a positive control at a concentration of 50 nM. (N=3) Gapmer design 1: 5’-lGlGlAlT 
dGdCdCdAdGdTdGdAdTdA lGlAlGlG-3’, Gapmer 2 design: 5’-lGlGlAlT dGdCdCdAdGdTdGdA lTlAlGlA-
3’, Gapmer 3 design: 5’-lGlGlAaT dGdCdCdAdGdTdGdA aTlAlGlA-3’, Gapmer design 4: 5’-lGlGlA 
dAdAdCdAdTdCdGdAdC lAlGlT-3’. (l – locked nucleic acid, d – deoxyribonucleotide, a – palmitoylated amino 
locked nucleic acid). COX-2 siRNA-sense strand: 5’-CAUUCCCUUCCUUCGAAAUdTdT-3’ and antisense 
strand: 5’-AUUUCGAAGGAAGGGAAUGdTdT-3’. 
  Hydrogels at different HA: chitosan ratios were prepared to modulate the release profile of fluorescent 
gapmers measured by a fluorescent plate reader. Incorporation efficiency was 96.1 - 97.2 %, with highest 
incorporation efficiency achieved with the hydrogel of HA/chitosan ratio of 7:3. A 5-day sustained release 
profile was shown with the HA-chitosan 7:3 hydrogel, while 5:5 hydrogel released over 3 days and 3:7 
hydrogel within 1 day (Figure 4). For the HA:chitosan 7:3 hydrogel, the total amount released was 101 %, and 
for the 5:5 and the 3:7 hydrogels 60 % and 43 %, respectively. The initial burst in first 4 hours for the 7:3 
hydrogel was 41%, whilst 5:5 and 3: 7 hydrogels were 56 % and 62 %, respectively. No loss of structural 
integrity was observed after release over the 5 day period demonstrated by non-detection of fragment bands 
(Supplementary Figure 4). The fainter band at day 5 can be attributed to the low amount released between day 
4 and day 5. 
 
Fig. 4. Accumulative release profiles of gapmer oligonucleotides in different hydrogel compositions. Cy5 
labelled gapmer (50 ug) was incorporated into hydrogels composed of different HA:chitosan ratios (7:3, 5:5 
and 3:7). 2 ml hydrogel was added into a 24-well plate and 0.5 ml PBS was used as release media. 
Fluorescence intensity of media was determined at an excitation wavelength of 650 nm and emission 
wavelength of 670 nm. Released gapmer amount was calculated using a standard calibration curve. (N=3). 
A hydrogel containing a COX-2 specific gapmer design 1 exhibited a sustained COX-2 inhibition over 
14 days. IL-1β was used to induce inflammation in primary OA chondrocytes and increased the COX-2 level 
more than 100-fold compared with non-treated cells (Figure 5). A second IL-1β administration to OA 
chondrocytes at day 7 was performed to compensate for the loss of IL-1β, asCOX-2 level decreased to 49% at 
day 6 compared to day 1. From day 3, a significant reduction of COX-2 expression level was observed for the 
COX-2 gapmer treated cells, with silencing maintained up to day 10. At day 14, the COX-2 specific gapmer 
group COX-2 expression level increased to a similar level to the mismatch control group, most probably due 
to the completion of the COX-2 inhibition effect of the released gapmers.  
  
Fig. 5. COX-2 cellular gene expression level from 1 to 14 days in primary OA chondrocytes below gapmer 
oligonucleotide loaded hydrogels. COX-2 gapmers were incorporated in a HA-based hydrogel (HA:chitosan 
of 7:3). Primary OA chondrocytes were treated with 10 ng/ml IL-1β to induce inflammation at day 0 and 7 
(arrows). At different time points, RNA was extracted for real time PCR analysis. COX-2 expression levels 
were normalized to non-treated groups. A hydrogel loaded with a mismatch gapmer sequence was used as 
negative control. Asterisk denotes significant differences between experimental and negative control groups 
(N=3). 
4. Discussion  
In this work, we introduce a novel HA-based hydrogel designed for the dual capacity for CD44-dependent 
chondrocyte binding and gene regulation for applications in the treatment of OA. The dual modality of 
chondrocytes engagement and simultaneous sustained release of gapmers for unassisted cell entry, potentiates 
interaction between drugs and cells required for enhanced tissue regeneration within a biodegradable 3-
dimensional scaffold.  
Current use of HA in OA treatment is mainly focused on chondroprotection, anti-inflammatory and 
friction reduction [21, 22]. HA-based hydrogels such as HA-fibrin [12], HA-chitosan [23] and methacrylated 
HA [24] hydrogels have been used for OA due to mechanical and biocompatibility properties as a natural 
component in knee joint. Typically, high molecular weight HA has been used to facilitate a more stable 
hydrogel matrix structure. There is also evidence showing the size of HA molecules and concentration are 
lower in OA patients with chronic or acute inflammation, and that the supply of high molecular weight HA 
can both stimulate the HA synthesis in synovium, and mediate chondrocyte proliferation and function [25].  
To our knowledge no previous studies have utilised HA-based hydrogels for active CD44-mediated 
binding of chondrocytes as an approach for OA tissue repair, which was based on our previous finding of 
higher CD44 engagement with high 900 kDa molecular weight HA [17]. Although it is termed as ‘binding’ in 
this work, and cell movement into hydrogel was not investigated in the present study, CD44 interactions may 
lead to active recruitment of chondrocytes into the porous network of hydrogel. A previous study has reported 
the use of hydrogel immobilized CD34 antibody to capture endothelial progenitor cells by utilizing receptor 
binding [26]. Incorporation of labile biomacromolecules such as antibodies as a method for cell binding or 
recruitment, however, is restricted by the necessity for conjugation and stability. The preferential binding of 
surrounding cells into a drug-containing 3-D matrix offers great potential in tissue regeneration applications 
as an alternative to loading patient-specific chondrocytes into the hydrogels before implantation that requires 
patient cell harvest. Previous reports have suggested the role of HA in the recruitment of CD44-expressing 
cancer cells in endogenous extracellular matrix possibly due to HA presence [27, 28]. However, there are no 
reports on CD44-expressing chondrocyte binding to HA-rich matrix and the application for OA treatment. 
 In our work the HA was modified for introduction of aldehyde groups to allow cross-linking with the 
carboxyl-bearing chitosan. The gelation process took ~ 2 minutes, suggesting potential use as an injectable 
soluble formulation in the joint for in situ gelation. An important consideration was to retain the HA 
conformation that allows effective interaction with CD44 that has previously been reported to be dependent 
on three carboxyl groups [29]. For instance, a 50 mol% HA modification of adipic acid dihyrazide has been 
shown to not bind CD44 [30]. In our work, a higher primary chondrocyte number, compared to the CD44-
expressing and CD44-negative cell line, was shown with increased 900 kDa HA content that is most probably 
attributed to the higher CD44-expression level determined in these cells. The isogenic MCF-7 cells were used 
as models to study HA-CD44 specific binding, so differences could be attributed to CD44 expression level 
only, with the CD44-expressing cells, in contrast to the CD44-negative MCF-7 cells, exhibiting a higher 
binding with a HA-rich matrix.  
The hydrogel was used to incorporate the polyanionic gapmers of ~6 kDa molecular weight. To our 
knowledge, this is the first demonstration of incorporation and sustained release of gapmers from a HA-based 
3-D scaffold. The hydrogel is a highly water-containing matrix that allows loaded small hydrophilic molecules 
to diffuse into the outer aqueous environment at a relatively rapid speed [31]. It is, therefore, unlikely that 
gapmers were physically entrapped within the matrix, but rather incorporated by electrostatic interactions 
between the phosphate backbone of the gapmer and the amino-bearing chitosan, that result in a high 
encapsulation efficiency of ~ 96.1 - 97.2 %. The release of gapmers can be attributed to the exchange of 
polyanions in the culture medium, which may occur in an in vivo environment due to anionic peptides or 
chloride ions in body fluids. The hydrogel with the highest HA percentage of 70 % displayed a more complete 
release and lower initial burst than the other compositions. This could be attributed to the tighter binding of 
the gapmers with higher chitosan contents, restricting release prior to hydrogel degradation, which may take 
more than 1 month [32]. The HA: chitosan 7:3 hydrogel was selected for subsequent silencing studies due to 
its favorable gapmer release profile and high chondrocyte binding.  
The attractive properties of gapmers are specificity, stability and ability for unassisted cell entry by the 
process of gymnosis to facilitate gene silencing. Gymnosis is the process of the cellular delivery of antisense 
oligodeoxynucleotides to cells, in the absence of any carriers or conjugation, that produces sequence-specific 
gene silencing [10]. This abrogates transfection agent inclusion and makes gapmers suitable for sustained 
release and subsequent entry into surrounding cells. Several gapmer designs were screened to select designs 
showing maximal COX-2 cellular gene silencing for downstream hydrogel studies. Palmitoylated gapmers 
were expected to have higher cell uptake due to the hydrophobic property of fatty acid that can bind to the cell 
membrane via hydrophobic interaction. However, it showed less uptake and silencing efficiency compared 
with the optimal non-modified gapmer. This could, among other factors (the insertion of different numbers of 
LNAs or different nucleotides in designs), be due to it being a saturated fatty acid derivative, in contrast to 
unsaturated fatty acid shown previously to enhance gene silencing [10].  
COX-2 is one of the main inflammatory targets in OA, and IL-1β has been widely used to induce 
inflammation in the OA model [33]. The COX-2 level is increased greatly by IL-1β compared with healthy 
knee joints. For OA treatment, COX-2 inhibitor drugs has become the most commonly prescribed treatment 
to relieve pain and slow the cartilage breakdown process [34]. In the COX-2 inhibition with gapmer loaded 
HA hydrogel experiment, COX-2 silencing effects were not apparent at day 1 after induction of 
inflammation using IL-1β. This may be due to time required for cellular uptake and mRNA gene silencing 
process and mRNA half-life. The unassisted delivery of gapmer relies on passive diffusion process and 
requires time to reach an effective concentration in the cytoplasm for mRNA cleavage [35], whilst the 
existing COX-2 mRNA requires time for degradation as mRNA has an approximate half-life of 7.1 h [36]. 
Results showed a 14-day COX-2 silencing effect despite a 5-day release profile, which can be attributed to 
the stability of gapmers in the cellular cytoplasm. Gapmers are flanked by locked nucleic acid modification, 
that give protection from endogenous enzymatic degradation, and, thus, can exert silencing for an extended 
period that has been shown previously to be 6-10 days [9]. In our work, the prolonged silencing effect was 
extended over 10 to 14 days, suggesting the hydrogel-mediated delivery was effective for prolonged gene 
silencing. Compared with current nonsteroidal anti-inflammatory drugs for OA treatment which are orally 
taken several times daily and may have gastrointestinal adverse reactions [37], the local sustained release of 
COX-2 gapmer may reduce drug dose frequency and minimize systemic toxicity. In this work, COX-2 was 
the silencing target for inhibition of inflammation. The oxidized hyaluronic acid and chitosan solutions have 
low viscosity, which should not present a problem as injectables for future in vivo studies. It is, however, not 
possible to inject the combined HA/chitosan mix due to the fast gelation of ~10 seconds. Simultaneous 
injections, however, of the two solutions is possible using a two compartment syringe to allow gelation in 
situ. A higher number of chondrocytes have been used (10 – 130 million cells/ml) in the literature for in vitro 
tissue regeneration applications [38] than used in our experiment (1 x 105 cells/well), however, the actual 
chondrocyte number in cartilage is ~ 14000 cells/mm3 [39], which equates to ~ 14 million cells/ml. The 
demonstrated CD44-mediated engagement with the hydrogel in this work suggests potential recruitment of 
chondrocytes that potentiates therapeutic delivery into cells. Moreover, we do not anticipate that increasing 
the dose of gapmers would be a problem. The mechanism driven by electrostatic incorporation into the 
hydrogel should allow higher levels of gapmer to be incorporated due to excess polycationic chitosan 
compared to the polyanionic gapmers used. 
Other gapmers targeting different targets such as aggrecan degradation protease ADAMTS5 (A 
disintegrin and metalloproteinase with thrombospondin motifs 5) can intervene in the cartilage breakdown 
pathway [40] and are a current focus of our work.  
In this study, we introduce a novel HA-hydrogel containing gapmer antisense oligonuclotides that has a 
dual modality of chondrocyte binding and gene silencing. A 5-day sustained release of COX-2 specific 
gapmers resulted into a 14-day COX-2 silencing effect in OA chondrocytes. The combined properties of 
chondrocyte binding, release and unassisted cellular entry of target-specific gapmers promotes this delivery 
platform for a wide panel of targets that are key regulators in OA.  
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 Supplementary Figures 
 
Figure 1. Determination of CD44 protein expression level on various cell types. Chondrocytes, 
CD44-expressing (CD44+) and CD44 negative (CD44-) MCF-7 cells were trypsinized and 
suspended in block buffer. FITC-CD44 human antibody was added into cell suspensions for 30 
min incubation and fluorescence intensity was measured as CD44 expression level using flow 
cytometry.  Flow cytometer used a laser wavelength of 488 nm and gate events of 10000 (N=3). 
 
 Figure 2. Viability of OA chondrocytes binding to hydrogels of different HA: chitosan ratio 
using an MTT assay. 5 x 104 cells were seeded on hydrogels of different HA:chitosan ratios (3:7, 
5:5 and 7:3) in 0.5 ml culture media. Total binding chondrocytes were collected after 36 h 
incubation and counted by NucleoCounter® NC-200. Live cell numbers were determined using 
an MTT assay with a calibration curve from non-treated cells. Viabilities were calculated as 
live cells/total cells (N=3).  
 Figure 3. Viability of OA chondrocytes treated with COX-2 gapmers. Chondrocytes were 
treated with 500 nM gapmers of different designs, and the viability evaluated after 24 h by an 
MTT assay with absorbance measured at 570 nm (N=3). 50 nM siRNA with 4 μl lipofectamine 
was used as a control group. Gapmer design 1: 5’-lGlGlAlT dGdCdCdAdGdTdGdAdTdA 
lGlAlGlG-3’, Gapmer 2 design: 5’-lGlGlAlT dGdCdCdAdGdTdGdA lTlAlGlA-3’, Gapmer 3 
design: 5’-lGlGlAaT dGdCdCdAdGdTdGdA aTlAlGlA-3’, Gapmer design 4: 5’-lGlGlA 
dAdAdCdAdTdCdGdAdC lAlGlT-3’. (l – locked nucleic acid, d – deoxyribonucleotide, a – 
palmitoylated amino locked nucleic acid). COX-2 siRNA-sense strand: 5’-
CAUUCCCUUCCUUCGAAAUdTdT-3’ and antisense strand: 5’-
AUUUCGAAGGAAGGGAAUGdTdT-3’.  
 Figure 4. Gapmer structural integrity study using gel electrophoresis. Gapmer design 1 (4 nmol) 
was incorporated into 2 ml hydrogel of 7:3 HA/chitosan ratio. The hydrogel was added into a 
24-well plate and 0.5 ml PBS was used as release medium. Released gapmers were loaded on 
a 20 % polyacrylamide gel and stained with SYBR gold. The molecular weights of gapmers 
were compared with GeneRuler Ultra Low Range DNA Ladder (ThermoFisher).  
 
